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Abstract
Background: Muckle-Wells-syndrome (MWS) is an autoinflammatory disease characterized by systemic and organ-
specific inflammation due to excessive interleukin (IL)-1 release. Inner ear inflammation results in irreversible
sensorineural hearing loss, if untreated. Early recognition and therapy may prevent deafness. The aims of the study
were to characterize the spectrum of hearing loss, optimize the otologic assessment for early disease and
determine responsiveness to anti-IL-1-therapy regarding hearing.
Methods: A single center prospective cohort study of children and adults with MWS was performed. Standardized
clinical, laboratory and otologic assessments including standard pure tone audiometry, additional high tone
thresholds, vestibular organ testing, tinnitus evaluation and functional disability classes were determined serially.
Pure-tone-average models were developed and evaluated. Risk factors for hearing loss and the impact of anti-IL-1
treatment were determined.
Results: A total of 23 patients with genetically confirmed MWS were included, of whom 63 % were females; 52 %
were children. At baseline all patients had active MWS; 91 % reported clinically impaired hearing with 74 % having
an abnormal standard assessment (0.5–4 kHz). In contrast, high frequency pure tone averages (HF-PTA) were
abnormal in all symptomatic patients including those with early hearing loss (sensitivity 100 %). Females were at
highest risk for hearing loss even after adjustment for age (p = 0.008). Treatment with IL-1 blockade resulted in
improved or stable hearing in 91 % of patients.
Conclusions: Early inner ear inflammation in MWS primarily affects the high frequencies, beyond the range of
standard otologic assessment tools. The HF-PTA is a sensitive tool to detect imminent hearing loss and monitor
treatment response.
Keywords: NLRP3 mutation, Muckle-Wells-Syndrome, Cryopyrin-associated periodic syndrome, Autoinflammatory
syndromes, Hearing loss, Inner ear, Pure tone average
Background
Muckle-Wells syndrome (MWS) is an autosomal domin-
ant autoinflammatory disease in the clinical spectrum of
cryopyrin-associated periodic syndrome (CAPS). CAPS
comprise the mildest form, familial cold autoinflamma-
tory syndrome (FCAS), the intermediate MWS and the
most severe phenotype chronic infantile neurological cu-
taneous and articular syndrome (CINCA) or neonatal-
onset multisystem inflammatory disease (NOMID) [1].
First described in 1962, MWS was characterized by the
triad of urticaria, deafness and reactive amyloid A (AA)
amyloidosis [2]. In 2001, Hoffman et al., reported gain-
of-function mutations in the NLRP3-gene (CIAS1) on
chromosome 1q44 encoding the protein NLRP3 (cryo-
pyrin) in MWS [3–5]. Subsequently NLRP3/cryopyrin
was identified to be a key protein of the multiprotein
cytoplasmic complex named inflammasome [6]. In
CAPS patients, impaired NLRP3/cryopyrin results in ex-
cessive release of the active form of interleukin (IL)-1β
[7], causing severe inflammatory symptoms including
fever, rash, conjunctivitis, headache, arthralgia/arthritis
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and fatigue [8]. Devastating organ disease of MWS in-
cludes amyloidosis and deafness [9].
Sensorineural hearing loss in MWS often rapidly pro-
gresses from mild high-tone deficits to complete deaf-
ness [10, 11]. Early hearing loss primarily affects high
frequencies of ≥ 6 kHz reflecting the characteristic high
sensitivity pattern of hair cells to injury as described in
other systemic conditions such as rheumatoid arthritis
and diabetes [12, 13]. Goldbach-Mansky and co-workers
were able to visualize the inflammatory injury in CAPS
on MRI studies [14, 15]. Early inner ear inflammation
and hearing loss may initially not impact communication
in quiet. Reports suggest the reversibility of early inner
ear inflammation and improved hearing with IL-1 block-
ade in MWS patients [11, 16–20]. MWS treatment op-
tions include anakinra [17], a short acting IL-1 receptor
antagonist and canakinumab, a fully human monoclonal
antibody providing selective and prolonged IL-1β block-
ade [21] and rilonacept, an IL-1 trap fusion protein [16].
Early detection of imminent hearing loss is crucial, yet
challenging. Traditionally, pediatric and adult screening
audiograms determine individual hearing thresholds at
the frequencies 0.5, 1.0, 2, and 3 or 4 kHz reflecting
those frequencies most relevant for speech discrimin-
ation. Hearing thresholds at each frequency are deter-
mined, and averaged in a single value, the so-called 4
pure tone average (4PTA: 0.5, 1, 2, and 4 kHz). This
commonly used approach has significant limitations for
the early detection of hearing loss in MWS, since the
frequencies affected earliest are above the test range and
therefore not included in the evaluation. However, early
detection of imminent hearing loss and immediate initi-
ation of targeted therapy may prevent progression to
deafness in children and adults with MWS. Thus, a tai-
lored assessment tool for detection of early hearing loss
in MWS is urgently needed.
Therefore, the aims of the study were 1) to characterize
the distinct pattern of hearing loss at diagnosis of MWS,
2) to modify the established standard 4PTA assessment
tool to the hearing loss characteristics of MWS patients
and assess its sensitivity in detecting hearing loss and 3) to
determine risk factors associated with hearing loss in
MWS and the effects of IL-1-inhibition.
Methods
A single-center cohort study of consecutive patients di-
agnosed with MWS between 4/2004 and 12/2007 was
performed. Pediatric and adult patients had to have a
clinical diagnosis of MWS and genetic confirmation of a
NRLP3 mutation. The clinical diagnosis was based on
the presence of MWS typical features of fever, non-
purulent conjunctivitis, urticaria-like rash, sensorineural
hearing loss, arthralgia/arthritis, fatigue coupled with
raised inflammatory markers. Mutations were determined
as previously described [22]. Exclusion criteria were 1) sig-
nificant medical conditions impacting on hearing other
than MWS and 2) age <3 years at diagnosis. Informed
consent was obtained from all patients for the DNA se-
quence analysis of their NLRP3 gene. The study was ap-
proved by the local ethics committee (Clinical Ethics
Committee at the University Hospital Tuebingen, REB No
326/2007B01).
Clinical features and disease activity
All MWS patients were diagnosed and followed accord-
ing to a standardized protocol by an interdisciplinary
tertiary care team. Demographic information included
age at diagnosis, gender, ethnicity and type of NLRP3
gene mutation. Clinical characteristics were documented
as previously reported [23]. Review of systems captured
constitutional symptoms of fever (pattern and duration)
and fatigue. Organ specific clinical characteristics includ-
ing headache, ocular symptoms of conjunctivitis, uveitis,
papilledema and other eye symptoms, sensorineural
hearing loss, oral ulcers, abdominal pain, arthralgia, arth-
ritis and myalgia and skin symptoms including erythema-
tous and cold-induced rash were collected. Proteinuria,
hematuria and renal failure requiring organ replacement
therapy were recorded. Inflammatory markers including C-
reactive protein (CRP) and serum amyloid A (SAA) were
determined in all patients. Disease activity was captured in
the previously reported MWS-Disease Activity Score
(MWS-DAS) [24]. MWS-DAS captures active MWS in 10
domains, nine of which reflect organ involvement of MWS
including fever, headache, eye involvement, hearing impair-
ment, oral ulcers, abdominal pain, renal disease, musculo-
skeletal disease, and rash in addition to the Patient Global
Assessment Score. The MWS-DAS attributes 0, 1, or 2
points to each level of disease activity. Two points are given
for severe symptoms, one point for mild symptoms, and
zero points for the absence of symptoms in a domain. As
previously determined, a MWS-DAS score of <10 points
reflects overall mild MWS disease, whereas a score >10
points is an indicator of severe MWS disease activity.
Hearing assessment
All patients had serial comprehensive otolaryngologic
assessments. Pure-tone audiometry was serially per-
formed for each ear separately using conventional, play
or behavioral audiograms. All adult patients were add-
itionally tested using speech audiometry, caloric vestibu-
lar stimulation and tinnitus handicap questioning. The
audiograms of members of the same family were com-
pared in order to capture the family-specific risk of pro-
gressive hearing loss. The audiologic examination
included air and bone conduction threshold for pure
tone frequencies of 0.125, 0.25, 0.5, 1, 2, 4, 6 and 8 kHz
and middle ear functional testing by impedance
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audiometry. Hearing threshold is defined as the dB value
at which sound is perceived at a given frequency. In
order to account for normal age-related hearing loss,
measured age-adjusted hearing thresholds were calcu-
lated (Additional file 1: Table S1).
Hearing assessment tools
Pure Tone Average – 4PTA
Pure tone thresholds at 0.5, 1, 2 and 4 kHz were mea-
sured at each time point for each ear. The thresholds
were summed and divided by 4 giving each frequency
equal weight in the score. An average was calculated for
each ear and examination time point (4PTA). Values
were considered abnormal if they differed by ≥ 10 dB
from normative hearing threshold levels (Additional file 1:
Table S1) established from large groups of individuals
matched in respect to age and frequency [25]. Comparison
to normative data has been used in rare disease popula-
tions before [26]. Because of very minor gender differ-
ences especially in the younger age groups, male and
female data were combined.
High frequency pure tone average – HF-PTA
High frequency pure tone average was determined by
measuring pure tone thresholds at 6 and 8 kHz and
averaging these thresholds giving each frequency equal
weight in the score (HF-PTA). Values were considered
abnormal if they differed by ≥ 10 dB from normative
hearing threshold levels (Additional file 2: Table S2)
established from large groups of individuals matched
with respect to age and frequency [25]. Because of very
minor genders differences especially in the younger age
groups, male and female control data were combined.
WHO functional disability associated with hearing loss
Functional disability associated with hearing loss was
evaluated according to the World Health Organization
(WHO) (Fig. 1). WHO grades of hearing impairment in
a patient are based on the 4PTA of the patient’s better
ear. They include: grade 0: no hearing impairment
(4PTA ≤ 25 dB), grade I: slight impairment (4PTA 26–
40 dB), grade II: moderate impairment (4PTA children
31–60 dB; adults 41–60 dB), grade III: severe impair-
ment (4PTA 61–80 dB) and grade IV profound hearing
impairment, (4PTA ≥81db) (Fig. 1). Hearing impairment
grades II to IV are considered disabling. Profound hearing
impairment constitutes deafness. Functional disability
levels were determined at baseline and at last follow-up.
Anti-IL-1 treatment
Anakinra therapy Patients were treated with anakinra
(Kineret; Amgen, Cambridge, UK) at dose of 100 mg/day
for ≥40 kg body weight or 1–2 mg/kg/day in patients
Fig. 1 World Health Organization (WHO) definition of functional disability associated with hearing loss and frequencies of daily noises. The graph
depicts common sources of noises including their frequencies and loudness. The WHO definition defines five severity grades of hearing
impairment based on the 4PTA of the patient’s better ear. 4PTA captures the most relevant frequencies for speech discrimination at 0.5, 1, 2, and
4 kHz. Hearing impairment grades II to IV are considered disabling. Profound hearing impairment constitutes deafness.
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<40 kg body weight. In children with persistent disease ac-
tivity, the anakinra dose was stepwise increased to a max-
imum of 8 mg/kg/day. Anakinra was self-administered by
subcutaneous injection once daily.
Canakinumab therapy Patients received canakinumab
subcutaneously 150 mg or 2 mg/kg for body weight
<40 kg every 8 weeks. In case of residual symptoms,
patients were maintained on a more intense dosing regi-
men (increase dose up to 600 mg s.c. or 8 mg/kg s.c
and/or increase of dosing frequency).
Outcome
Primary outcome Hearing loss was defined as increased
threshold of ≥10 dB for any of the age-adjusted pure tone
average for the frequencies 0.5, 1, 2 and 4 kHz (4-PTA)
and the two high frequencies 6 and 8 kHz (HF-PTA).
Secondary outcomes 1) Improved or stable hearing was
defined as a) decrease in hearing threshold by ≥ 20 dB in
one frequency or by ≥10 dB in two, or more consecutive
frequencies for improved hearing or b) absence of wors-
ening of hearing at last follow-up. 2) Worsening of hear-
ing was defined as increase in hearing threshold
by ≥20 dB in one frequency, or by ≥10 dB in two or
more consecutive frequencies, in accordance with defini-
tions used in previous studies [15].
Statistical analysis
Descriptive statistics were performed; results were re-
ported as frequencies with percentages, means with
standard deviations, or medians with ranges. Univariate
parametric analyses utilized Fisher’s exact and chi-square
analyses for categorical data and students T-test for con-
tinuous variables. Non-parametric tests were performed
where appropriate. Paired univariable analyses were
conducted to determine treatment responses. Repeated
measures linear regression analysis was performed for
comparative and predictive modeling of hearing thresh-
olds to account for paired ears within patients. All tests
considered p <0.05 as statistically significant. Statistical
analyses were performed using SAS statistical software
for Windows Version 9.3 (SAS Institute, Cary, North
Carolina, USA).
Results
A total of 23 patients with clinically and genetically con-
firmed MWS were included in the study; 65 % were fe-
males. The median age at diagnosis was 18 years with a
range from 3–72 years. Fifty-two percent were children
age <18 years. Three NLRP3 mutations were found in
this cohort: 61 % had the c.937G>A (p.Glu313Lys)
formerly known as E311K mutation, 22 % the c.1049C>T
(p.Thr350Met), formerly known as T348M and 17 % the
c.598G>A (p.Val200Met), formerly known as V198M
mutation (Table 1).
Clinical features, disease activity and treatment
All patients had active disease at diagnosis reflected in a
median MWS-DAS of 8. Most commonly seen clinical
features were arthralgia (96 %), eye involvement (91 %)
and headache (83 %). Clinical hearing loss was reported
by 91 % of patients. Other features included oral ulcers
(78 %), rash (65 %) and myalgia (52 %). At baseline, the
mean SAA level was 68.7 mg/dl, mean CRP level
2.2 mg/dl (Table 1). Anakinra cohort: 10 patients (43 %)
received anakinra treatment; these were three males and
seven females. The median age at diagnosis was 17 years
with a range from 3 to 44 years. The most common mu-
tation was the c.937G>A (p.Glu313Lys) mutation
present in 5 (50 %) patients; 3 (30 %) had the c.1049C>T
(p.Thr350Met) and 2 (20 %) the c.598G>A (p.Val200-
Met) mutation. Canakinumab cohort: 13 patients (57 %),
5 males and 8 females, were treated with canakinumab.
The median age at diagnosis was 34 years with a range
between 3 and 72 years. Three different NLRP3 muta-
tions were found: c.937G>A (p.Glu313Lys) in nine and
c.1049C>T (p.Thr350Met) and c.598G>A (p.Val200Met)
in two respectively.
Table 1 Demographic, clinical and laboratory findings and





Median age at diagnosis of MWS [years] (range) 18 (3–72)
Children ≤18 years at diagnosis (%) 12 (52)
Females (%) 15 (65)
NLRP3 mutation
• c.937G>A (p.Glu313Lys) (%) 14 (61)
• c.1049C>T (p.Thr350Met) (%) 5 (22)
• c.598G>A (p.Val200Met) (%) 4 (17)
Overall disease activity
Median MWS-DAS at baseline (range) 8 (6–16)
Laboratory markers
Mean SAA at baseline in mg/l (std), (nl* <1) 6.87 (1.43)
Mean CRP at baseline in mg/l (std), (nl* <0.05) 0.22 (0.17)
Treatment
IL-1 Inhibition (%) 23/23 (100)
Anakinra (%) 10 (43)
Canakinumab (%) 13 (57)
*nl: normal value
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Hearing assessment
At baseline, 21/23 MWS patients (91 %) had sensori-
neural hearing loss by audiogram, correspondingly 42/46
hearing assessments (single ears) were abnormal. All 11
adults had abnormal hearing assessments (100 %, 22/22
ears), while only 10/12 children (83 %, 20/24 ears) had
evidence of sensorineural hearing loss. Hearing thresh-
olds at baseline varied significantly across ages and
frequencies (Fig. 2). Comparison of hearing thresholds
by frequency demonstrated significant differences be-
tween lower and higher frequencies, even after adjust-
ing for age and gender (p <0.001). All patients had
normal tympanic membrane mobility, normal middle
ear pressure by impedance audiometry and normal




Fig. 2 Variation of hearing thresholds across ages and frequencies in patients with Muckle-Wells syndrome (MWS). a Comparison of hearing
threshold within a family with MWS. Audiogram of a 5 year-old child with MWS (a-1): Standard hearing assessment in the 4PTA range including
0.5, 1, 2, and 4 kHz was normal (light gray area). In contrast the proposed HF-PTA captured a dramatic early high frequency hearing loss with increased
hearing thresholds at 6 and 8 kHz (dark grey area). The child’s 37-year old father reported hearing impairment. The corresponding audiogram (a-11)
revealed abnormally increased hearing thresholds across all frequencies (light and dark grey areas). In the father advanced MWS associated
hearing loss is captured not only by HF-PTA but also by standard 4PTA. b Comparison of hearing thresholds of standard 4 pure-tone-
average (4PTA) and proposed high frequency pure-tone-average (HF-PTA) in children and adults with MWS and age-matched healthy
controls across the age spectrum. Normal hearing thresholds captured in 4PTA and HF-PTA increase with age (4PTA grey line, HF-PTA
black line). MWS patients of all ages have significantly higher 4PTAs (black circles) and HF-PTAs (grey triangles) even after adjusting for
age-specific normal hearing thresholds
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4PTA assessments
At baseline, 34/46 (74 %) MWS hearing assessments
demonstrated an abnormal 4PTA, including 22/22 adult
patient hearing assessments (100 %) and 12/24 (50 %)
children ears. The median baseline 4PTA was 28 (range
0–72); at last follow-up, the median 4PTA was 26 (range
0–56) (Table 2).
HF-PTA
At baseline, 42 MWS patient assessments demonstrated
an abnormal HF-PTA (91%). An abnormal HF-PTA was
found in 22/22 adult assessments (100 %) and in 20/24
(83 %) in children. The median baseline HF-PTA was 45
(range 0–114); at last follow-up, the median HF-PTA
was 43 (range 0–114) (Table 2).
Sensitivity of PTA assessments
The sensitivity of the 4PTA to detect clinical hearing
loss was 81 %. The 4PTA assessment exclusively missed
children with early severe hearing loss affecting primarily
high frequencies. The HF-PTA testing identified 100 %
of patients.
WHO functional disability associated with hearing loss
At baseline, 8 patients – all children – had no hearing
impairment (WHO grade 0), two patients, both adults,
showed slight impairment (WHO grade I), eight – four
children and four adults – had moderate (grade II), four
had severe hearing impairment (WHO grade III), all
were adults, and one adult had profound hearing impair-
ment (WHO grade IV).
At last follow-up, 9 patients – all children – presented
with no hearing impairment (WHO grade 0), one adult
showed slight (WHO grade I), nine patients, six adults
and three children, had moderate (grade II), three pa-
tients, all adults (WHO grade III), and one adult still
had profound hearing impairment (WHO grade IV). So
one child reversed hearing loss during treatment.
a
b
Fig. 3 Effect of anti-IL-1 therapy on hearing assessments in patients with MWS. a Comparison of two different anti-IL-1 therapy regimens. A total
of 11 assessments (ears) of 9 patients improved with anti-IL1 therapy; 4/9 were children, five were adults. None of the patients had worsening of
the contralateral ear. Improvement occurred with both treatment regimens. All but two patients with hearing improvement were females. Overall,
worsening was exclusively observed in adult patients, a male and a female. Both patients had received anakinra therapy. b Responsiveness to
change: Comparison between 4PTA and HF-PTA follow-up assessments after exposure to anti-IL-1 therapy. 4PTA and HF-PTA was calculated in all
MWS patients following anti-IL-1 therapy. Hearing improved in five children and six adults, most commonly captured by HF-PTA (10/11), either by
HF-PTA only (5/10, light grey bars) or also by the standard 4PTA (5/10, medium grey bars). Hence, a total of 91 % of improved assessments were
detected by HF-PTA, while just in one patient improvement was detected by standard 4PTA only. Worsening was not documented in children,
but deteriorated in two adults. In both, this was detected by standard 4PTA, in one also in the HF-PTA
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Risk factors for hearing loss in MWS
Female gender (p = 0.008), earlier age at diagnosis (p
<0.001), and affection of high compared to low frequen-
cies (p = <0.001) were found to be significantly associ-
ated with hearing loss in a repeated measures linear
regression model to account for paired ears within pa-
tients. Young age was primarily associated with high fre-
quency hearing loss, while older patients had evidence
of abnormal hearing thresholds across all frequencies.
Female gender was an independent risk factor for hear-
ing loss in MWS.
Effect of anti-IL-1 therapy on hearing loss
A total of 44/46 (96 %) patient ears had improved or
stable hearing assessments as defined above when
treated with anti-IL1 therapy. Improvement was docu-
mented in 11 ears, six of which were treated with cana-
kinumab and five with anakinra. Stable hearing was
documented for 33 ears, 20 of which were treated with
canakinumab and 13 with anakinra. Only two ears wors-
ened significantly; these include one of an 18-year-old
male and one of a 37-year-old female, both treated with
anakinra. The contralateral ears for the two patients
remained stable (Fig. 3).
Discussion
This is the first study to systematically analyze the
spectrum of hearing loss in a large prospective cohort of
MWS patients across all ages. A key finding is that early
inner ear inflammation in MWS primarily affects high
frequencies above 4 kHz and remains undetected when
using standard assessment approaches (4PTA). There-
fore, optimized testing for early hearing loss in MWS
has to include high frequency hearing thresholds of 6
and 8 kHz (HF-PTA) in order to significantly increase
the sensitivity of the hearing assessment and to allow for
the recognition of early MWS associated hearing loss
due to inflammatory injury. This is particularly import-
ant in children, since early on in life MWS solely affects
high frequencies. In fact, the study determined that earl-
ier age at diagnosis was significantly associated with the
development of hearing loss. Rapid onset of therapy may
control the inflammation thus greatly reducing the risk
of inner ear damage and deafness in MWS [24]. The
study confirmed that anti-IL-1 therapy is effective in sta-
bilizing or even improving sensorineural hearing loss,
particularly in younger patients. Improved hearing is
best confirmed when utilizing the optimized assessment
tool HF-PTA in addition to standard testing. Reversibil-
ity of hearing loss follows the MWS pattern and is most
commonly seen in high frequencies. The study also
highlighted that female MWS patients of all ages are at
significantly higher risk for hearing loss and deafness
compared to males. Importantly, females of all ages had
a good response to anti-IL-1 therapy.
Onset and progression of hearing loss in MWS has a
distinct pattern (Fig. 2a). The inflammatory attack pri-
marily affects high frequencies. A similar hearing loss
pattern has been described in other inflammatory dis-
eases including rheumatoid arthritis [12], metabolic dis-
eases including diabetes [13, 27] and thyroid disease [28]
and exposure to ototoxic drugs [29]. Hearing thresholds
in the high frequencies of the pure tone audiogram are
particularly relevant for speech discrimination and com-
munication, especially in a noisy environment [30]. Af-
fected MWS patients report impaired hearing; however
standard evaluation may remain normal. Detection of
early hearing loss in MWS mandates testing of high fre-
quency hearing thresholds. Early inner ear injury may
Table 2 Audiologic findings in a cohort of pediatric and adult
MWS patients at baseline and following treatment with anti-IL-
1-therapy utilizing the standard 4PTA and the proposed high
frequency (HF-PTA) instrument
Patients N = 23
Assessments
(ears) N = 46
Hearing loss at baseline
Patients with clinical hearing loss (%) 21/23 (91)
Ears (assessments) with hearing loss (total) (%) 42/46 (91)
Adults with hearing loss (%) 11/11 (100)
• Abnormal assessments (adults) (%) 22/22 (100)
Children with hearing loss (%) 10/12 (83)
•Abnormal assessments (children) (%) 20/24 (83)
Hearing thresholds at baseline
4-frequency pure tone average (4PTA),
median (range)*
28 (0–72)
Number of abnormal 4PTA assessments (%)* 34/46 (74)
•Adult assessments with abnormal 4PTA (%) 22/22 (100)
•Pediatric assessments with abnormal 4PTA (%) 12/24 (50)
High Frequency HF-PTA median (range)* 45 (0–114)
Abnormal HF-PTA hearing assessments (%) 42/46 (91)
•Adult assessments with abnormal HF-PTA (%) 22/22 (100)
•Pediatric assessments with abnormal HF-PTA (%) 20/24 (83)
Hearing thresholds at last follow-up
4 Pure Tone Average (4PTA); median (range)* 26 (0–56)
Abnormal 4PTA assessments (%) 34/46 (74)
High Frequency HF-PTA; median (range)* 43 (0–114)
Abnormal HF-PTA assessments (%) 42/46 (83)
Sensitivity of hearing assessments
Detection of clinical hearing loss by 4PTA 81 %
Detection of clinical hearing loss by HF-PTA 100 %
* Each patient is represented twice, since each ear had a separate hearing
assessment; all values are adjusted for age (Additional files 1 and 2: Tables S1
and S2)
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remain unnoticed when using the current testing routine
(4PTA). The proposed HF-PTA has a higher sensitivity
for early disease and should therefore be considered in
all ages, but particularly in younger MWS patients. An
extended hearing threshold testing (0.5-8 kHz) is in-
creasingly used for noise induced hearing loss [31] and
when monitoring for potential ototoxicity with antibi-
otics and chemotherapeutic agents [29]. Overall, MWS
patients require comprehensive otolaryngologic assess-
ments. Serial pure tone thresholds including air- and
bone conduction thresholds for frequencies of 0.125,
0.25, 0.5, 1, 2, 4, 6 and 8 kHz should be determined by
pure-tone audiometry using conventional, play or behav-
ioral audiograms. Speech audiometry, caloric vestibular
stimulation, tinnitus assessments and middle ear func-
tional testing by impedance audiometry should be
included.
Prevention of deafness as a result of inner ear inflam-
mation in children and adults is a key task when treating
patients with MWS. Anti-IL-1 therapy was effective in
stabilizing progression of hearing loss in this cohort,
similarly to what was reported by others caring for pa-
tients with CAPS [15, 32–34]. In our study, reversibility
of inner ear disease was found to follow a characteristic
pattern with early improvement in the high frequencies.
Change was best detected by HF-PTA and may be
missed when testing standard frequencies only. Overall,
it appears that there is a window of opportunity at the
time of primary involvement of high frequencies. Cor-
respondingly, younger patients were most likely to re-
spond to treatment. The window may vary between
different NLRP3 mutations [11]. Overall, younger age
was clearly identified to be a risk factor associated with
sensorineural hearing loss. Females with MWS appear to
be at higher risk for hearing loss at all ages, correspond-
ingly they were previously found to have overall more
severe disease as captured by the MWS disease activity
score (MWS-DAS) [24]. Reasons for this observation are
unknown. The unbalanced gender ratio in this study
only reflects the gender of the consecutive patients in-
cluded into this study at time of inclusion. As the gender
distribution in other larger cohorts of CAPS patients is
roughly balanced (own complete CAPS cohort: 55 %
males, β-confident registry: 54 % females) in CAPS no
gender preference can be observed. Also, type of muta-
tion is associated with different degrees of hearing loss,
as described previously [11]. Interestingly, in this study
all but two patients with evidence of hearing improve-
ment after anti-IL-1 therapy were females.
There are several imitations to the study. The number
of patients tested is small, only 23 children and adults
were included. However, MWS is a very rare condition. A
comprehensive, standardized assessment and therapy
protocol was applied prospectively to all patients allowing
for the capture of detailed clinical and audiological data at
baseline and following therapy. The age spectrum was
wide with relatively few patients per age group threatening
the generalizability of the results. However, the clinical
spectrum of CAPS is also wide and varies further between
NLRP3 gene mutation types regarding impact on hearing
[24]. The study included three different mutations and al-
most balanced numbers of children and adults. The study
did not include additional objective measures of hearing
such as otoacoustic emissions, brainstem evoked response
audiometry and gadolinium-enhanced magnetic reson-
ance imaging (MRI) studies. However, these tests have
limited utility as generalizable screening and monitoring
tools for centers worldwide. In addition, MRI studies of
the inner ear in children commonly require anesthesia.
Conclusions
Diagnostic evaluation and monitoring of hearing abilities
in patients with MWS mandates a comprehensive oto-
laryngologic approach. The addition of HF-PTA to the
standard 4PTA pure tone threshold testing allows for
early recognition of imminent hearing loss and should
prompt the rapid start of anti-IL-1 therapy for preven-
tion of damage in particular in the high risk MWS
populations.
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